Policy Developments - The National Medical Products Administration (NMPA) approved the registration of 308 medical device products as of March 2025, including 248 domestic Class III medical devices, 34 imported Class III medical devices, 19 imported Class II medical devices, and 7 medical devices from Hong Kong, Macau, and Taiwan [1] Drug Approvals - Chengdu Saijing Bio's ursodeoxycholic acid oral suspension has been approved as the first domestic generic Class 3.1 new drug for treating cystic fibrosis-associated liver disease (CFALD), filling a gap in the market for this indication [2] - Kowa Company's pemafibrate tablets have been approved in China for the treatment of dyslipidemia [3] - Merck Sharp & Dohme (MSD) announced that its nine-valent HPV vaccine has received approval for male use in China, targeting males aged 16-26, enhancing public awareness of HPV infections in men [5] Capital Market - Zhongjie Chaorun completed a Pre-A round financing of several million yuan, primarily for clinical trials of its artificial meniscus implant and commercialization of its innovative meniscus suturing device [4] Financial Reports - Aoyang Health reported a 2024 revenue of 2.01 billion yuan, a year-on-year decrease of 7.54%, with a net profit of 40.56 million yuan, down 18.36% [6] - Novogene announced a total revenue of 2.111 billion yuan for 2024, a year-on-year increase of 5.45%, with a net profit of 197 million yuan, up 10.52% [7] - Tianyi Medical reported a revenue of 419 million yuan for 2024, a year-on-year increase of 9.98%, but a net loss of 744,000 yuan [8] - Luoxin Pharmaceutical disclosed a net loss of 962 million yuan for 2024, despite a revenue increase of 11.99% to 2.647 billion yuan [9] - Dongxing Medical reported a revenue of approximately 435 million yuan for 2024, a slight increase of 0.4%, with a net profit of about 97.42 million yuan, up 0.21% [10] Public Sentiment - Xinbang Pharmaceutical announced the resignation of independent director Zhou Jun, with the company reporting a revenue of 6.032 billion yuan for 2024, down 6.63%, and a net profit of 101 million yuan, down 64.70% [11] - Shuangcheng Pharmaceutical warned of potential delisting risk due to expected negative net profit and revenue below 300 million yuan for 2024 [12]

近日， 中杰超润（北京）医药科技有限公司 （以下简称"中杰超润"）宣布完成数千万元 Pre-A轮融资 ，投 资方为清源创投，长海资本担任独家财务顾问。本轮融资资金将主要用于公司核心产品人工半月板植入器械的 临床推进，以及创新半月板缝合器的商业化。 报名：首届全球眼科大会 | 议程更新 报名：首届全球骨科大会 | 议程更新 报名：首届全球心血管大会 | 奖项申报 合作伙伴征集：2025全球手术机器人大会 # 关于 中杰超润 中杰超润成立于2020年11月，总部位于北京市昌平区，是一家以从事医药制造业为主的企业。主营业务为 新 材料技术研发、生物基材料技术研发及相关产品的销售，专注于人工仿生材料的技术制备、研发和应用， 现 已在膝关节治疗方向成功研发出 人工仿生半月板的制备。 中杰超润在人工半月板领域处于领先地位，其核心 产品 Supermenis ® 人工半月板 是一款全球First in class的半月板植入器械产品。 产品与技术 Supermenis ® 人工半月板。该产品采用自主研发的超强韧耐磨材料，其仿生设计在含水量、微观结构、力学 性能、自润滑性、生物相容性等方面均优于现有产品和天然半月板。通过对大 ...